No Data
No Data
Hong Kong stock market anomaly | Remegen (09995) rose by more than 5% again. The company stated that all businesses are progressing normally, and the controlling shareholder intends to increase shareholding in the company.
According to the WiseNews app, Remegen (09995) has risen more than 5% again, although this week's cumulative decline has exceeded 23%. As of press time, it has risen 5.46% to HKD 16.62, with a turnover of HKD 49.4734 million. In terms of news, Remegen issued a notice of abnormal fluctuations in stock trading. According to market rumors, some of the company's products' external authorization progress did not meet expectations. After the company's self-inspection, all business operations are currently proceeding as usual, without involving hot market concepts. The company also responded that it has a certain amount of cash reserves; commercialization brings a certain scale of cash flow; has adequate bank credit; and potential international cooperation may also come.
Remegen (09995): The company's A-share stock trading has had abnormal fluctuations, but all of the company's business is currently progressing normally.
Remegen (09995) announced that the company's A shares will be traded on July 8, 9, and 10, 2024...
RemeGen Reports Unusual Share Price Drop
HK stocks saw unusual movement as the biomedical sector rallied, boosted by bullish policies for innovative drugs. There are still multiple catalysts for the sector in the second half of the year.
According to the Wise Money APP, biopharmaceutical stocks rebounded collectively. As of the press release, Remegen (09995) rose by 8.06%, to HKD 14.74; Kexing Biotech-B (06990) rose by 7.46%, to HKD 142.6; Genscript Biotech (01548) rose by 5.08% to HKD 9.52, and Junshi Bio (01877) rose by 4.17% to HKD 13. News-wise, on July 5th, the State Council's executive meeting reviewed and approved the "Implementation Plan for Supporting the Development of Innovative Drugs throughout the Entire Chain." Previously, the National Medical Insurance Bureau released the "First Launch Price of New Marketed Chemical Drugs".
Hong Kong stock market anomaly | Remegen (09995) rebounds more than 7%. The company states that all operations are proceeding normally. The controlling shareholder plans to increase shareholding by up to 20 million Chinese yuan.
Remegen (09995) rebounded more than 7% and as of press time, rose 7.04%, at HKD 14.6, with a turnover of HKD 18.1965 million.
Remegen (09995.HK) stocks are experiencing abnormal fluctuations in trading, but all business operations of the company are currently progressing normally.
On July 10th, Gelunhui announced that the closing price of Remegen's (09995.HK) stocks had deviated from the expected value by more than 30% for three consecutive trading days, from July 8th to July 10th, 2024. This is considered an abnormal fluctuation in stock trading according to the relevant provisions of the Shanghai Stock Exchange Trading Rules and the Science and Technology Innovation Board Stock Abnormal Trading Real-time Monitoring Measures. Market rumors suggest that the progress of some of the company's products authorized for external use did not meet expectations. However, according to the company's self-inspection, all of its businesses are proceeding normally, and do not involve any hot concepts in the market. After further verification, the company did not find any other issues.
No Data